STOCKHOLM, SWEDEN--(Marketwire - June 05, 2012) - Sobi has decided to refinance its
existing credit facility either by issuing a SEK denominated bond up to SEK
500 M or by entering into a new revolving credit facility with SEB and
Nordea.
The purpose of the refinancing is to improve the financial flexibility and
to extend the maturity profile. The refinancing will replace existing bank
debt and will not increase Sobi's total debt.
Sobi has appointed Nordea as Joint Bookrunner and Co-ordinator together
with SEB as Joint Bookrunner to investigate a bond issue. The lead banks
Nordea and SEB have committed to provide a credit facility in a
corresponding amount in the event that Sobi does not proceed with the bond
issue.
Swedish Orphan Biovitrum (Sobi)
Sobi is a leading integrated biopharmaceutical company dedicated to
bringing innovative therapies and services to improve the health of rare
disease patients and their families. The product portfolio comprises about
45 marketed products as well as projects in the late clinical phase. Key
therapeutic areas are Inflammation and Genetics & Metabolism. In 2011, Sobi
had revenues of SEK 1.9 billion and around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at
www.sobi.com.
The information above has been published pursuant to the Swedish Securities
Market Act and/or the Financial Instruments Trading Act. The information
was released for public distribution on 5 June 2012 at 16.50 CET.
Sobi Press Release on June 5 in pdf format:
http://hugin.info/134557/R/1617484/516151.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality
of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
[HUG#1617484]
